U.S. Hospitality Stock News

Union Pacific (UNP) opened Q1 2026 earnings season with Q4 2025 revenue of US$6.1 billion and basic EPS of US$3.12, capping a trailing twelve month period in which EPS reached US$12.00 on revenue of US$24.5 billion and earnings grew 5.8% year over year. Over recent quarters, the company has seen revenue move in a tight range between US$6.0 billion and US$6.2 billion while quarterly basic EPS tracked between US$2.71 and US$3.16. This gives a clear view of how the earnings line has behaved...

Nano-X Imaging’s April 2026 update showed fourth-quarter 2025 sales rising to US$3.72 million while net loss widened to US$33.37 million, including a US$17.53 million impairment, alongside full-year 2025 losses and the appointment of incoming CFO Guy Nathanzon after Ran Daniel’s planned departure. At the same time, a new clinical collaboration with Meir Medical Center to further validate the Nanox.ARC system highlights management’s focus on strengthening the technology’s real-world...

Cathay General Bancorp (CATY) opened 2026 with Q1 revenue of US$196.6 million and basic EPS of US$1.30, alongside net income of US$86.9 million. This followed a year in which trailing twelve month revenue reached US$769.6 million and EPS came in at US$4.86. Over the past year, revenue has moved from US$691.3 million to US$769.6 million on a trailing basis, while TTM EPS increased from US$3.97 to US$4.86. This gives investors a clearer view of how the latest quarter fits within a steadily...

Universal Technical Institute recently reported that new student enrollments have been weaker than anticipated and that it plans to step up investments to defend its position in technical education, a move expected to weigh on free cash flow margins. This combination of softer demand and rising investment needs has intensified questions about how effectively the company is deploying capital to support long-term performance. We’ll now examine how concerns over weaker new student enrollment...

Joby Aviation (NYSE:JOBY) is partnering with Reuben Brothers to build an air taxi vertiport and passenger lounge at Century Plaza in Los Angeles. The project marks Joby's first integration of an eVTOL vertiport directly into a residential development. The plan uses existing helipad infrastructure and adds a dedicated passenger lounge aimed at everyday urban users. Joby Aviation operates in the electric vertical take off and landing, or eVTOL, air taxi space, where companies are working to...

Sprinklr (NYSE:CXM) has launched its Spring 2026 Release, introducing advanced AI-driven features for its customer experience platform. The release adds autonomous agent evaluation tools designed to assess and monitor AI performance in customer service. Sprinklr also announced a new alliance with CreatorIQ to integrate creator intelligence with its unified social media management capabilities. Sprinklr enters this product release cycle with its shares at $4.84 and a value score of 2,...

ZORYVE (roflumilast) cream has received a strong, high certainty recommendation in the American Academy of Dermatology’s new pediatric atopic dermatitis guidelines. This is the AAD’s first set of clinical practice guidelines focused on pediatric atopic dermatitis, giving the product formal visibility in a key treatment area. The endorsement supports ZORYVE’s role as an evidence backed option for long term use in children with atopic dermatitis. For Arcutis Biotherapeutics (NasdaqGS:ARQT),...

CME Group (NasdaqGS:CME) reported record average daily volumes and record revenues in Q1 2026. All six asset classes on the platform reached record activity levels in the quarter. The company is rolling out new options on Eris SOFR Swap futures and expanding Equity Index Dividend futures. Regulators approved an expanded cross margining arrangement with DTCC for U.S. Treasury and interest rate derivatives. CME Group sits at the center of global futures and options trading, connecting clients...

Heartland Express (HTLD) opened 2026 with Q1 results that extend a run of soft profitability, capped by trailing 12 month revenue of US$805.7 million and a basic EPS loss of US$0.67 tied to a net loss of US$52.5 million. Over the past six reported quarters, quarterly revenue has ranged from US$179.4 million to US$259.9 million, while basic EPS has moved between a loss of US$0.02 and a loss of US$0.25. This sets up a story where investors are weighing ongoing losses against forecasts that...

Martin Midstream Partners (MMLP) opened 2026 with Q1 results that keep the focus squarely on profitability, as the latest trailing 12 month figures show total revenue of US$716.1 million and a loss of US$14.4 million, or basic EPS of US$0.37. Over recent quarters, the partnership has seen quarterly revenue range from US$168.7 million to US$192.5 million, while basic EPS has moved between a profit of US$0.09 and losses of up to US$0.21. This sets up an earnings release where investors are...

Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI achieved a 20% objective response rate, 87% disease control rate, and manageable safety in heavily pretreated patients with unresectable colorectal cancer, while also advancing a Biologics License Application for ozekibart in conventional chondrosarcoma. These data position ozekibart as a potential first-in-class DR5 agonist with activity across multiple hard-to-treat solid...

Popular (BPOP) has just posted another solid quarter, with Q4 2025 revenue of US$751.8 million and basic EPS of US$3.54, setting the tone as investors look at the new Q1 2026 reporting period. The bank has seen quarterly revenue move from US$689.4 million in Q4 2024 to US$751.8 million in Q4 2025, while basic EPS over that same stretch climbed from US$2.51 to US$3.54, giving you a clear sense of how the income line has scaled alongside the top line. Taken together with an improved net profit...

Katahdin Bankshares (KTHN) has just put another quarter on the board, with Q4 2025 revenue of US$11.9 million and basic EPS of US$0.99 setting the tone after a year in which trailing net income reached US$10.7 million on revenue of US$44.3 million. Over recent periods the company has seen revenue move from US$9.5 million and EPS of roughly US$0.56 in Q4 2024 to US$11.9 million and US$0.99 respectively in Q4 2025. Trailing basic EPS for the last reported twelve months reached about US$3.37...

American Riviera Bancorp (ARBV) opened 2026 with Q1 results that build on a solid finish to last year, with Q4 2025 revenue at about US$14.4 million and basic EPS of roughly US$0.80, while trailing twelve month revenue stood at about US$50.4 million and EPS at roughly US$2.18. Over recent quarters, revenue has moved from about US$10.7 million in Q4 2024 to US$14.4 million in Q4 2025, and basic EPS has shifted from roughly US$0.35 to US$0.80. This sets up a story where higher net income and...

Recently, Surgery Partners reduced its earnings guidance after encountering slower surgical case growth, a less favorable payer mix, and reimbursement pressures across its facilities. An important angle is that the company is still prioritizing higher-acuity procedures and robotics investments, suggesting a focus on reshaping its case mix despite these operational challenges. We’ll now explore how this guidance cut, driven by slower case growth and payer mix headwinds, affects Surgery...

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...

Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...

Farmers & Merchants Bancorp (FMAO) has put fresh numbers on the board, with Q4 2025 revenue of about US$31.9 million and basic EPS of US$0.70, supported by net income of US$9.7 million as the latest marker ahead of its Q1 2026 reporting period. The business has seen revenue move from US$26.6 million and EPS of US$0.59 in Q4 2024 to US$31.9 million and EPS of US$0.70 in Q4 2025. Trailing 12 month earnings growth of 29.4% and a 27.6% net margin frame a profitability profile that many investors...

Southern Missouri Bancorp (SMBC) opened Q3 2026 with Q2 results that put revenue and earnings in clear focus, reporting total revenue of US$48.0 million and basic EPS of US$1.62 on net income of US$18.1 million. The company has seen revenue move from US$41.7 million with EPS of US$1.10 in Q1 2025 to US$45.1 million and EPS of US$1.40 in Q4 2025, then to US$48.0 million and EPS of US$1.62 in Q2 2026. This latest report can be viewed as part of a steady earnings story that investors can now...

ONE Gas (OGS) has drawn fresh attention after its recent trading session, with the stock closing at $88.76. For investors, the move brings added focus to how the regulated utility’s fundamentals line up. See our latest analysis for ONE Gas. The latest move to $88.76 comes after a 14.93% 90 day share price return and a 16.97% total shareholder return over the past year, hinting that momentum has been building rather than fading. If this kind of steady utility performance has you thinking about...

Thermo Fisher Scientific (TMO) has just put fresh numbers on the table, with Q4 2025 revenue of US$12.2b and basic EPS of US$5.22 setting the tone against a trailing twelve month EPS of US$17.78 on revenue of US$44.6b, alongside net income of US$6.7b. The company has seen quarterly revenue move from US$10.6b in Q3 2024 to US$12.2b in Q4 2025, while basic EPS over the same period went from US$4.27 to US$5.22. This gives investors a clear read on top line scale and earnings power as they assess...

Kearny Financial (KRNY) has just reported Q3 2026 results with quarterly revenue in the low US$40 million range and basic EPS of about US$0.15, set against a trailing twelve month EPS of US$0.52 that reflects the shift back into profitability. Over recent periods, revenue has moved from US$36.96 million in Q1 2025 to US$42.97 million in Q2 2026, while quarterly EPS has stepped from roughly US$0.10 to just over US$0.15. This gives investors a clearer read on how earnings now sit relative to...

First Bancorp (FBNC) opened 2026 with Q1 results that put the focus squarely on the income statement, reporting total revenue of US$119.2 million and basic EPS of US$1.13, backed by trailing twelve month revenue of US$393.3 million and EPS of US$2.93. Over recent periods the company has seen quarterly revenue move from US$65.2 million in Q4 2024 to US$104.7 million in Q1 2025, US$108.8 million in Q2, US$86.2 million in Q3 and US$79.2 million in Q4, while EPS shifted from US$0.09 to US$0.88,...

Belite Bio recently initiated a rolling New Drug Application submission to the U.S. FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1, following completion of a Phase 3 trial and multiple regulatory designations including Breakthrough Therapy and Orphan Drug status. This step positions tinlarebant as a potential first approved treatment for Stargardt disease and highlights Belite Bio’s advancing regulatory and commercialization plans in rare retinal...